RENCA/carbonic anhydrase-IX: A murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma

Carbonic anhydrase-IX (CA-IX) is a cell surface tumor-associated antigen expressed by most clear cell renal cell carcinomas (RCCs). The specificity and the prognostic value of CA-IX provide impetus to create a mouse model of CA-IX-expressing RCC for testing CA-IX-targeted therapies against RCC. A re...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 2006-11, Vol.68 (5), p.1132-1138
Main Authors: Shvarts, Oleg, Janzen, Nicolette, Lam, John S., Leppert, John T., Caliliw, Randy, Figlin, Robert A., Belldegrun, Arie S., Zeng, Gang
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Carbonic Anhydrase IX
Carbonic Anhydrases - analysis
Carbonic Anhydrases - biosynthesis
Carcinoma, Renal Cell - chemistry
Carcinoma, Renal Cell - enzymology
Carcinoma, Renal Cell - pathology
Disease Models, Animal
Kidney Neoplasms - chemistry
Kidney Neoplasms - enzymology
Kidney Neoplasms - pathology
Kidneys
Medical sciences
Mice
Mice, Inbred BALB C
Nephrology. Urinary tract diseases
Tumors of the urinary system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carbonic anhydrase-IX (CA-IX) is a cell surface tumor-associated antigen expressed by most clear cell renal cell carcinomas (RCCs). The specificity and the prognostic value of CA-IX provide impetus to create a mouse model of CA-IX-expressing RCC for testing CA-IX-targeted therapies against RCC. A retrovirus encoding the human CA-IX gene was used to transduce the murine RCC line, RENCA. In vivo growth kinetics and CA-IX expression were compared between RENCA and RENCA/CA-IX using heterotopic, metastatic, and orthotopic models. Transduction of RENCA created the RENCA/CA-IX line with nearly 100% CA-IX surface expression. In the heterotopic model, subcutaneous injection of 500,000 and 50,000 cells led to tumor formation at 2 to 2.5 weeks after injection, with similar growth kinetics between the two cell lines at either cell number. In the pulmonary metastatic model, a similar number of metastases was noted after inoculation of RENCA and RENCA/CA-IX. In the orthotopic model, autopsy revealed a CA-IX-expressing renal tumor, as well as CA-IX-expressing metastases to the lungs, liver, contralateral kidney, intestines, and lymph nodes. In all the above models, the RENCA/CA-IX tumors retained expression of CA-IX, as demonstrated by immunohistochemistry staining. RENCA/CA-IX is the first tumor model that manifests in immunocompetent Balb/c mice and stably expresses a defined kidney cancer-associated antigen. It maintains antigen expression, forms metastases, and produces reliable tumor growth kinetics equivalent to that of its parental cell line.
ISSN:0090-4295
1527-9995
DOI:10.1016/j.urology.2006.08.1073